Shares of Paratek Pharmaceuticals ($PRTK@US) are trading higher on Thursday morning after the company said their NUZYRA was added to the CDC plague guidelines for treatment, pre-exposure prophylaxis, and postexposure prophylaxis of primary bubonic plague infections. Shares of the company are up 25.2% at press time.
